FOLH1 and Alzheimer disease: The selected parameters were then applied to the reconstructed SPECT series (24, 48, and 72 h post-injection) of 20 patients who received either [<sup>177</sup>Lu]Lu-DOTA-TATE (n = 10) or [<sup>177</sup>Lu]Lu-PSMA-I&T (y = 10) treatment, in order to evaluate its impact on AD estimates.